The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the sod1-g93a microglia model of amyotrophic lateral sclerosis

Journal of Immunology

Volumn 190, Issue 10, 2013, Pages 5187-5195

  Apolloni, Savina ^a,b   Parisi, Chiara ^a,b   Pesaresi, Maria Grazia ^b   Rossi, Simona ^b,c   Carri, Maria Teresa ^b,c   Cozzolino, Mauro ^b,d   Volonte, Cinzia ^a,b   D'Ambrosi, Nadia ^a,b  

^a CNR   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER ZINC SUPEROXIDE DISMUTASE; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN P67; PURINERGIC P2X7 RECEPTOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; INFLAMMATION; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CELLS, CULTURED; CYTOKINES; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; INFLAMMATION; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; MICROGLIA; MOTOR NEURONS; NADPH OXIDASE; NEUROPEPTIDES; OXIDATIVE STRESS; PHOSPHOPROTEINS; PHOSPHORYLATION; PURINERGIC P2X RECEPTOR ANTAGONISTS; PYRIDINES; RAC GTP-BINDING PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, PURINERGIC P2X7; SUPEROXIDE DISMUTASE; TETRAZOLES;

EID: 84877823786     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1203262     Document Type: Article

References (43)

1. Cozzolino, M., M. G. Pesaresi, V. Gerbino, J. Grosskreutz, and M. T. Carri. 2012. Amyotrophic lateral sclerosis: new insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid. Redox Signal. 17: 1277-1330.
2. Henkel, J. S., D. R. Beers, W. Zhao, and S. H. Appel. 2009. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol. 4: 389-398.
3. Ilieva, H., M. Polymenidou, and D. W. Cleveland. 2009. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 187: 761-772.
4. Bedard, K., and K. H. Krause. 2007. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 87: 245-313. (Pubitemid 46209993)
5. Block, M. L. 2008. NADPH oxidase as a therapeutic target in Alzheimer's disease. BMC Neurosci. 9(Suppl. 2): S8.
6. Hordijk, P. L. 2006. Regulation of NADPH oxidases: the role of Rac proteins. Circ. Res. 98: 453-462.
7. Harraz, M. M., J. J. Marden, W. Zhou, Y. Zhang, A. Williams, V. S. Sharov, K. Nelson, M. Luo, H. Paulson, C. Schoneich, and J. F. Engelhardt. 2008. SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J. Clin. Invest. 118: 659-670. (Pubitemid 351206555)
8. Boillée, S., and D. W. Cleveland. 2008. Revisiting oxidative damage in ALS: microglia, Nox, and mutant SOD1. J. Clin. Invest. 118: 474-478. (Pubitemid 351206538)
9. Wu, D. C., D. B. Ré, M. Nagai, H. Ischiropoulos, and S. Przedborski. 2006. The inflammatory NADPH oxidase enzyme modulates motor neuron degeneration in amyotrophic lateral sclerosis mice. Proc. Natl. Acad. Sci. USA 103: 12132-12137. (Pubitemid 44215823)
10. Marden, J. J., M. M. Harraz, A. J. Williams, K. Nelson, M. Luo, H. Paulson, and J. F. Engelhardt. 2007. Redox modifier genes in amyotrophic lateral sclerosis in mice. J. Clin. Invest. 117: 2913-2919. (Pubitemid 47529621)
11. Valdmanis, P. N., E. Kabashi, P. A. Dion, and G. A. Rouleau. 2008. ALS predisposition modifiers: knock NOX, who's there? SOD1 mice still are. Eur. J. Hum. Genet. 16: 140-142.
12. Li, Q., N. Y. Spencer, N. J. Pantazis, and J. F. Engelhardt. 2011. Alsin and SOD1 (G93A) proteins regulate endosomal reactive oxygen species production by glial cells and proinflammatory pathways responsible for neurotoxicity. J. Biol. Chem. 286: 40151-40162.
13. Di Virgilio, F., S. Ceruti, P. Bramanti, and M. P. Abbracchio. 2009. Purinergic signalling in inflammation of the central nervous system. Trends Neurosci. 32: 79-87.
14. Skaper, S. D., P. Debetto, and P. Giusti. 2010. The P2X7 purinergic receptor: from physiology to neurological disorders. FASEB J. 24: 337-345.
15. Weisman, G. A., J. M. Camden, T. S. Peterson, D. Ajit, L. T. Woods, and L. Erb. 2012. P2 receptors for extracellular nucleotides in the central nervous system: role of P2X7 and P2Y2 receptor interactions in neuroinflammation. Mol. Neurobiol. 46: 96-113.
16. Volonté, C., S. Apolloni, S. D. Skaper, and G. Burnstock. 2012. P2X7 receptors: channels, pores and more. CNS Neurol. Disord. Drug Targets 11: 705-721.
17. Volonté, C., S. Apolloni, M. T. Carri, and N. D'Ambrosi. 2011. ALS: focus on purinergic signalling. Pharmacol. Ther. 132: 111-122.
18. Amadio, S., S. Apolloni, N. D'Ambrosi, and C. Volonté. 2011. Purinergic signalling at the plasma membrane: a multipurpose and multidirectional mode to deal with amyotrophic lateral sclerosis and multiple sclerosis. J. Neurochem. 116: 796-805.
19. Yiangou, Y., P. Facer, P. Durrenberger, I. P. Chessell, A. Naylor, C. Bountra, R. R. Banati, and P. Anand. 2006. COX-2, CB2 and P2X7- immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol. 6: 12.
20. Casanovas, A., S. Hernández, O. Tarabal, J. Rosselló, and J. E. Esquerda. 2008. Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis. J. Comp. Neurol. 506: 75-92. (Pubitemid 350293491)
21. D'Ambrosi, N., P. Finocchi, S. Apolloni, M. Cozzolino, A. Ferri, V. Padovano, G. Pietrini, M. T. Carri, and C. Volonté. 2009. The proinflammatory action of microglial P2 receptors is enhanced in SOD1 models for amyotrophic lateral sclerosis. J. Immunol. 183: 4648-4656.
22. Gandelman, M., H. Peluffo, J. S. Beckman, P. Cassina, and L. Barbeito. 2010. Extracellular ATP and the P2X7 receptor in astrocyte-mediated motor neuron death: implications for amyotrophic lateral sclerosis. J. Neuroinflammation 7: 33.
23. Saura, J., J. M. Tusell, and J. Serratosa. 2003. High-yield isolation of murine microglia by mild trypsinization. Glia 44: 183-189. (Pubitemid 37484470)
24. Cozzolino, M., V. Stagni, L. Spinardi, N. Campioni, C. Fiorentini, E. Salvati, S. Alema, and A. M. Salvatore. 2003. p120 Catenin is required for growth factordependent cell motility and scattering in epithelial cells. Mol. Biol. Cell 14: 1964-1977. (Pubitemid 36583546)
25. Kalyanaraman, B., V. Darley-Usmar, K. J. Davies, P. A. Dennery, H. J. Forman, M. B. Grisham, G. E. Mann, K. Moore, L. J. Roberts, II, and H. Ischiropoulos. 2012. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. Free Radic. Biol. Med. 52: 1-6.
26. Leto, T. L., S. Morand, D. Hurt, and T. Ueyama. 2009. Targeting and regulation of reactive oxygen species generation by Nox family NADPH oxidases. Antioxid. Redox Signal. 11: 2607-2619.
27. Allen, W. E., G. E. Jones, J. W. Pollard, and A. J. Ridley. 1997. Rho, Rac and Cdc42 regulate actin organization and cell adhesion in macrophages. J. Cell Sci. 110: 707-720. (Pubitemid 27156320)
28. Wilkinson, B. L., and G. E. Landreth. 2006. The microglial NADPH oxidase complex as a source of oxidative stress in Alzheimer's disease. J. Neuroinflammation 3: 30.
29. Friedle, S. A., V. M. Brautigam, M. Nikodemova, M. L. Wright, and J. J. Watters. 2011. The P2X7-Egr pathway regulates nucleotide-dependent inflammatory gene expression in microglia. Glia 59: 1-13.
30. Kim, E. K., and E. J. Choi. 2010. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 1802: 396-405.
31. Chung, Y. H., K. M. Joo, H. C. Lim, M. H. Cho, D. Kim, W. B. Lee, and C. I. Cha. 2005. Immunohistochemical study on the distribution of phosphorylated extracellular signal-regulated kinase (ERK) in the central nervous system of SOD1G93A transgenic mice. Brain Res. 1050: 203-209. (Pubitemid 40922735)
32. Ayala, V., A. B. Granado-Serrano, D. Cacabelos, A. Naudí, E. V. Ilieva, J. Boada, V. Caraballo-Miralles, J. Lladó, I. Ferrer, R. Pamplona, and M. Portero-Otin. 2011. Cell stress induces TDP-43 pathological changes associated with ERK1/2 dysfunction: implications in ALS. Acta Neuropathol. 122: 259-270.
33. Perlson, E., G. B. Jeong, J. L. Ross, R. Dixit, K. E. Wallace, R. G. Kalb, and E. L. Holzbaur. 2009. A switch in retrograde signaling from survival to stress in rapid-onset neurodegeneration. J. Neurosci. 29: 9903-9917.
34. Yang, E. J., J. H. Jiang, S. M. Lee, S. C. Yang, H. S. Hwang, M. S. Lee, and S. M. Choi. 2010. Bee venom attenuates neuroinflammatory events and extends survival in amyotrophic lateral sclerosis models. J. Neuroinflammation 7: 69.
35. Dewil, M., V. F. dela Cruz, L. Van Den Bosch, and W. Robberecht. 2007. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1 (G93A)-induced motor neuron death. Neurobiol. Dis. 26: 332-341. (Pubitemid 46561336)
36. Philips, T., and W. Robberecht. 2011. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 10: 253-263.
37. Boillée, S., K. Yamanaka, C. S. Lobsiger, N. G. Copeland, N. A. Jenkins, G. Kassiotis, G. Kollias, and D. W. Cleveland. 2006. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312: 1389-1392. (Pubitemid 43839552)
38. Turner, B. J., and K. Talbot. 2008. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog. Neurobiol. 85: 94-134.
39. Riboldi, G., M. Nizzardo, C. Simone, M. Falcone, N. Bresolin, G. P. Comi, and S. Corti. 2011. ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog. Neurobiol. 95: 133-148.
40. Phani, S., D. B. Re, and S. Przedborski. 2012. The Role of the Innate Immune System in ALS. Front. Pharmacol. 3: 150.
41. Honore, P., D. Donnelly-Roberts, M. Namovic, C. Zhong, C. Wade, P. Chandran, C. Zhu, W. Carroll, A. Perez-Medrano, Y. Iwakura, and M. F. Jarvis. 2009. The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice. Behav. Brain Res. 204: 77-81.
42. Takenouchi, T., K. Sekiyama, A. Sekigawa, M. Fujita, M. Waragai, S. Sugama, Y. Iwamaru, H. Kitani, and M. Hashimoto. 2010. P2X7 receptor signaling pathway as a therapeutic target for neurodegenerative diseases. Arch. Immunol. Ther. Exp. (Warsz.) 58: 91-96.
43. Liao, B., W. Zhao, D. R. Beers, J. S. Henkel, and S. H. Appel. 2012. Transformation from a neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp. Neurol. 237: 147-152.